PT2949658T - Péptidos que ligam especificamente o recetor de hgf (cmet) e utilizações dos mesmos - Google Patents

Péptidos que ligam especificamente o recetor de hgf (cmet) e utilizações dos mesmos

Info

Publication number
PT2949658T
PT2949658T PT15157779T PT15157779T PT2949658T PT 2949658 T PT2949658 T PT 2949658T PT 15157779 T PT15157779 T PT 15157779T PT 15157779 T PT15157779 T PT 15157779T PT 2949658 T PT2949658 T PT 2949658T
Authority
PT
Portugal
Prior art keywords
cmet
peptides
specifically bind
hgf receptor
bind hgf
Prior art date
Application number
PT15157779T
Other languages
English (en)
Inventor
C Ladner Robert
K Sato Aaron
T Dransfield Daniel
Original Assignee
Bracco Suisse Sa
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco Suisse Sa, Dyax Corp filed Critical Bracco Suisse Sa
Publication of PT2949658T publication Critical patent/PT2949658T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
PT15157779T 2003-03-03 2004-03-03 Péptidos que ligam especificamente o recetor de hgf (cmet) e utilizações dos mesmos PT2949658T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45158803P 2003-03-03 2003-03-03

Publications (1)

Publication Number Publication Date
PT2949658T true PT2949658T (pt) 2018-10-18

Family

ID=32962606

Family Applications (1)

Application Number Title Priority Date Filing Date
PT15157779T PT2949658T (pt) 2003-03-03 2004-03-03 Péptidos que ligam especificamente o recetor de hgf (cmet) e utilizações dos mesmos

Country Status (13)

Country Link
US (6) US20050214859A1 (pt)
EP (4) EP2949658B1 (pt)
JP (4) JP5466350B2 (pt)
AU (2) AU2004217894B2 (pt)
CA (1) CA2517939C (pt)
CY (1) CY1120683T1 (pt)
DK (2) DK2284180T3 (pt)
ES (3) ES2396368T3 (pt)
HU (1) HUE039154T2 (pt)
PL (2) PL1944312T3 (pt)
PT (1) PT2949658T (pt)
SI (1) SI2949658T1 (pt)
WO (1) WO2004078778A2 (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
CA2513044A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
PT2949658T (pt) * 2003-03-03 2018-10-18 Bracco Suisse Sa Péptidos que ligam especificamente o recetor de hgf (cmet) e utilizações dos mesmos
NO20034350D0 (no) * 2003-09-29 2003-09-29 Amersham Health As Optisk avbilding av kolorektal kreft
US20060008844A1 (en) * 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
EP1810037B1 (en) * 2004-10-20 2010-07-21 PEAS Institut AB Assessment of biological activity of hepatocyte growth factor (hgf)
US8236761B2 (en) 2006-07-07 2012-08-07 Washington State University Research Foundation C-Met receptor regulation by angiotensin IV (AT4) receptor ligands
WO2008005531A2 (en) * 2006-07-07 2008-01-10 Washington State University Research Foundation C-met receptor regulation by angiotensin iv (at4) receptor ligands
US8389482B2 (en) 2007-01-30 2013-03-05 New York University Short peptides useful for treatment of ischemia/reperfusion injury and other tissue damage conditions associated with nitric oxide and its reactive species
CA2685553C (en) 2007-05-16 2017-03-28 Ge Healthcare As Peptide imaging agents
GB0718957D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Optical imaging agents
GB0718967D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Peptide imaging agents
US20100196272A1 (en) 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
GB0918321D0 (en) 2009-10-20 2009-12-02 Ge Healthcare As Cyclic peptide synthesis
KR20120101054A (ko) 2009-11-05 2012-09-12 유니버시티 오브 버지니아 페이턴트 파운데이션 암에 대한 바이오마커로서 플렉틴-1을 검출하기 위한 조성물 및 방법
GB201013808D0 (en) * 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
GB201103696D0 (en) 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201116733D0 (en) 2011-09-28 2011-11-09 Ge Healthcare As Peptide margin imaging agents
GB201116862D0 (en) 2011-09-30 2011-11-09 Ge Healthcare As Infusion imaging method
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
WO2014074907A1 (en) * 2012-11-09 2014-05-15 Indi Molecular, Inc. C-met-specific capture agents, compositions, and methods of using and making
CN105209054A (zh) 2013-04-18 2015-12-30 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
EP3434277A1 (en) 2013-06-17 2019-01-30 Armo Biosciences, Inc. Method for assessing protein identity and stability
EP3035903B1 (en) 2013-08-20 2018-08-22 Anutra Medical, Inc. Syringe fill system and method
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
AU2014311432A1 (en) 2013-08-30 2016-03-03 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP3062881B1 (en) 2013-10-28 2019-10-02 NGM Biopharmaceuticals, Inc. Cancer models and associated methods
RU2016122957A (ru) 2013-11-11 2017-12-19 Армо Байосайенсиз, Инк. Способы применения интерлейкина-10 для лечения заболеваний и расстройств
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
US10806803B2 (en) 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
WO2016023895A1 (en) * 2014-08-11 2016-02-18 Miti Biosystems GmbH Cyclic peptides expressed by a genetic package
WO2016049044A1 (en) * 2014-09-22 2016-03-31 National Health Research Institutes Use of 5-methoxytryptophan as diagnostic agent of inflammatory diseases
CN107001438A (zh) 2014-10-14 2017-08-01 阿尔莫生物科技股份有限公司 白细胞介素‑15组合物及其用途
EP3209320B1 (en) 2014-10-22 2023-03-08 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
KR20180020141A (ko) 2015-05-28 2018-02-27 아르모 바이오사이언시스 인코포레이티드 암 치료에 사용되는 peg화된 인터류킨-10
WO2016196211A1 (en) 2015-05-29 2016-12-08 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
KR20220062668A (ko) 2015-06-15 2022-05-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 노화와 연관된 질환을 치료하기 위한 방법 및 조성물
CN108025040A (zh) 2015-08-25 2018-05-11 阿尔莫生物科技股份有限公司 使用白介素-10治疗疾病和病症的方法
AU2017273857B2 (en) * 2016-06-01 2021-08-19 Athira Pharma, Inc. Compounds
US20190151483A1 (en) 2016-07-25 2019-05-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Methods of making 18f-labeled precursors and peptides, labeled c-met binding peptides, and methods of use thereof
CA3036424C (en) * 2016-09-13 2023-01-17 Daiichi Sankyo Company, Limited Thrombospondin 1-binding peptide
CN109789183A (zh) 2016-09-29 2019-05-21 Aebi有限公司 治疗性多靶向构建体及其用途
GB201804835D0 (en) * 2018-03-26 2018-05-09 Ge Healthcare As Formulation and method of preparation
AU2020291197A1 (en) 2019-06-14 2022-01-27 Edinburgh Molecular Imaging Limited Compounds and methods of use
KR20220131221A (ko) 2019-11-13 2022-09-27 아뮤닉스 파마슈티컬스, 인크. 바코드화된 xten 폴리펩티드 및 이의 조성물, 및 이의 제조 방법 및 사용 방법
JP7162853B1 (ja) 2021-07-02 2022-10-31 ペプチスター株式会社 液相ペプチド合成用担体結合ペプチドの分析方法
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4131648A (en) 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4180646A (en) 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4391797A (en) 1977-01-05 1983-07-05 The Children's Hospital Medical Center Systems for the controlled release of macromolecules
US4718433A (en) 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
DE3313946A1 (de) 1983-04-15 1984-10-18 Schering AG, 1000 Berlin und 4709 Bergkamen Mikropartikel und gasblaeschen enthaltende ultraschall-kontrastmittel
DE3313947A1 (de) 1983-04-15 1984-10-18 Schering AG, 1000 Berlin und 4709 Bergkamen Mikropartikel und gasblaeschen enthaltende ultraschall-kontrastmittel
DE3834705A1 (de) 1988-10-07 1990-04-12 Schering Ag Ultraschallkontrastmittel aus gasblaeschen und fettsaeure enthaltenden mikropartikeln
US4900540A (en) 1983-06-20 1990-02-13 Trustees Of The University Of Massachusetts Lipisomes containing gas for ultrasound detection
US4899755A (en) 1985-05-08 1990-02-13 The General Hospital Corporation Hepatobiliary NMR contrast agents
MX174467B (es) 1986-01-23 1994-05-17 Squibb & Sons Inc 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
IE61591B1 (en) 1987-12-29 1994-11-16 Molecular Biosystems Inc Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production
US4844882A (en) 1987-12-29 1989-07-04 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5118797A (en) 1989-08-28 1992-06-02 E. R. Squibb & Sons, Inc. Rhenium tris dioxime complexes
WO1991003200A1 (en) 1989-08-28 1991-03-21 The General Hospital Corporation Hydroxy-aryl metal chelates for diagnostic nmr imaging
US5123414A (en) 1989-12-22 1992-06-23 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5230882A (en) 1989-12-22 1993-07-27 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5305757A (en) 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5773024A (en) 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5871959A (en) * 1989-12-27 1999-02-16 The United States Of America As Represented By The Department Of Health And Human Services Method of producing hepatocycte growth factor/scatter factor and related cell lines
CA2034042C (en) 1990-01-18 1999-08-17 Adrian D. Nunn Boronic acid adducts of rhenium dioxime and technetium-99m dioxime complexes containing a biochemically active group
US5556610A (en) 1992-01-24 1996-09-17 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method
US5445813A (en) 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
US5578292A (en) 1991-11-20 1996-11-26 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
IN172208B (pt) 1990-04-02 1993-05-01 Sint Sa
US5183653A (en) 1990-04-13 1993-02-02 E. R. Squibb & Sons, Inc. Boronic acid adducts of metal dioxime complexes useful in labelling proteins and other amine-containing compounds
US5137928A (en) 1990-04-26 1992-08-11 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
AU636481B2 (en) 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
US5173298A (en) 1990-09-27 1992-12-22 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
US5849261A (en) 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
JP2774378B2 (ja) 1991-02-08 1998-07-09 ダイアテク，インコーポレイテッド 映像用テクネチウム−９９ｍ標識化ポリペプチド
ES2180535T3 (es) 1991-02-22 2003-02-16 American Cyanamid Co Identificacion de un nuevo gen de tirosina quinasa receptora humana.
GB9106686D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
GB9106673D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
DE69219331T3 (de) 1991-06-03 2001-06-07 Nycomed Imaging As Verbesserungen im bezug auf kontrastmittel
AU675050B2 (en) 1991-07-05 1997-01-23 Nycomed Imaging As Improvements in or relating to contrast agents
US5808091A (en) 1991-10-29 1998-09-15 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia localizing moiety
GB9200387D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
GB9200388D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
GB9200391D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
IL104084A (en) 1992-01-24 1996-09-12 Bracco Int Bv Sustainable aqueous suspensions of pressure-resistant and gas-filled blisters, their preparation, and contrast agents containing them
US5861301A (en) 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
PT642580E (pt) * 1992-05-18 2003-01-31 Genentech Inc Variantes de factor de crescimento dos hepatocitos
US5316921A (en) * 1992-05-18 1994-05-31 Genentech, Inc. Single-chain hepatocyte growth factor variants
AU693767B2 (en) * 1992-08-10 1998-07-09 Cambridge Neuroscience, Inc. Inhibitors of cell proliferation, their preparation and use
BR9207175A (pt) 1992-10-28 1995-12-12 Genentech Inc Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero
US5608110A (en) 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
AU683485B2 (en) 1993-07-02 1997-11-13 Molecular Biosystems, Inc. Method for making encapsulated gas microspheres from heat denatured protein in the absence of oxygen gas
JPH09500140A (ja) 1993-07-19 1997-01-07 レゾリューション・ファーマスーティカルズ・インコーポレーテッド Ｎ▲下３▼ｓ立体配置を有するヒドラジノ型放射性核種キレート形成剤
US5798091A (en) 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
US5574140A (en) 1993-09-03 1996-11-12 Resolution Pharmaceutical Inc. Hydrazino-type N2 S2 chelators
CN1068229C (zh) 1993-12-15 2001-07-11 勃勒柯研究有限公司 超声对比介质、含该介质的对比剂及方法
GB9402867D0 (en) 1994-02-15 1994-04-06 Nycomed Imaging As Improvements in or relating to contrast agents
DK0751992T3 (da) 1994-03-08 2006-03-06 Human Genome Sciences Inc Karendotelvækstfaktor 2
JP2891647B2 (ja) 1994-03-11 1999-05-17 株式会社日本触媒 有機スルフィド化合物及びその製造方法
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US5582814A (en) 1994-04-15 1996-12-10 Metasyn, Inc. 1-(p-n-butylbenzyl) DTPA for magnetic resonance imaging
AU2263295A (en) 1994-04-20 1995-11-16 Nycomed Salutar, Inc. Contrast agents
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US5650135A (en) 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US5662885A (en) 1994-07-22 1997-09-02 Resolution Pharmaceuticals Inc. Peptide derived radionuclide chelators
GB9417941D0 (en) 1994-09-06 1994-10-26 Nycomed Imaging As Improvements in or relating to contrast agents
US5556939A (en) 1994-10-13 1996-09-17 Merck Frosst Canada, Inc. TC or RE radionuclide labelled chelate, hexapeptide complexes useful for diagnostic or therapeutic applications
US6245530B1 (en) 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
WO2002060950A2 (en) 1994-11-14 2002-08-08 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
US6403088B1 (en) 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US6221839B1 (en) 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
US6333021B1 (en) 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
DE4445065A1 (de) 1994-12-07 1996-06-13 Diagnostikforschung Inst Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung
IL116328A (en) 1994-12-16 1999-09-22 Bracco Research Sa Frozen suspension of gas microbubbles in frozen aqueous carrier for use as contrast agent in ultrasonic imaging
TW319763B (pt) 1995-02-01 1997-11-11 Epix Medical Inc
GB9502065D0 (en) 1995-02-02 1995-03-22 Nycomed Imaging As Contrast media
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
WO1996040285A1 (en) 1995-06-07 1996-12-19 Imarx Pharmaceutical Corp. Novel targeted compositions for diagnostic and therapeutic use
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
AU710696C (en) 1995-09-08 2002-10-24 Genentech Inc. VEGF-related protein
AU1116297A (en) 1995-11-08 1997-05-29 Immunex Corporation Flk-1 binding protein
US5837680A (en) 1996-02-16 1998-11-17 Children's Medical Center Corporation Pharmaceutical compositions comprising troponin subunits, fragments and analogs thereof and methods of their use to inhibit angiogenesis
EA001135B1 (ru) 1996-02-19 2000-10-30 Нюкомед Имагинг А/С Усовершенствования в области контрастных агентов
NZ331629A (en) 1996-04-01 2000-04-28 Epix Medical Inc Bioactivated diagnostic imaging contrast agents
MXPA99001053A (es) 1996-08-02 2002-03-11 Nycomed Imaging As Mejoramientos en o que se relacionan con agentes de contraste.
TW320761B (en) * 1996-10-03 1997-11-21 Mos Electronics Taiwan Inc Manufacturing method of high density DRAM with cylindrical stack capacitor
DE69738406T2 (de) 1996-10-21 2008-12-04 Ge Healthcare As Verbesserungen in oder an Kontrastmitteln
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
ES2257771T3 (es) 1996-10-28 2006-08-01 Amersham Health As Agentes de contraste.
WO1998018495A2 (en) 1996-10-28 1998-05-07 Marsden, John, Christopher Improvements in or relating to diagnostic/therapeutic agents
WO1998018498A2 (en) 1996-10-28 1998-05-07 Marsden, John, Christopher Improvements in or relating to diagnostic/therapeutic agents
WO1998018497A2 (en) 1996-10-28 1998-05-07 Nycomed Imaging As Contrast agents
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
GB9708265D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
US6264917B1 (en) 1996-10-28 2001-07-24 Nycomed Imaging As Targeted ultrasound contrast agents
EP0973552B1 (en) 1996-10-28 2006-03-01 Amersham Health AS Improvements in or relating to diagnostic/therapeutic agents
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US5919967A (en) 1997-04-11 1999-07-06 Epix Medical, Inc. Process for synthesizing phosphodiesters
DE19717904A1 (de) 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
US6245318B1 (en) 1997-05-27 2001-06-12 Mallinckrodt Inc. Selectively binding ultrasound contrast agents
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
GB9712525D0 (en) 1997-06-16 1997-08-20 Nycomed Imaging As Method
DE69838334T2 (de) 1997-06-18 2008-06-12 Merck & Co., Inc. (A New Jersey Corp.) Kdr, ein menschlicher tyrosin kinase rezeptor
IL134985A0 (en) 1997-10-02 2001-05-20 Epix Medical Inc A method for contrast enhanced diagnostic imaging
CA2313390A1 (en) 1997-12-09 1999-06-17 Children's Medical Center Corporation Peptide antagonists of vascular endothelial growth factor
US6165458A (en) 1997-12-26 2000-12-26 Pharmaderm Laboratories Ltd. Composition and method for dermal and transdermal administration of a cytokine
WO1999039738A1 (en) 1998-02-09 1999-08-12 Bracco Research S.A. Targeted delivery of biologically active media
CA2320339A1 (en) 1998-02-11 1999-08-19 Resolution Pharmaceuticals Inc. Angiogenesis targeting molecules
US20020136721A1 (en) * 1998-02-17 2002-09-26 Schwall Ralph H. Hepatocyte growth factor receptor antagonists and uses thereof
ES2241313T3 (es) 1998-03-31 2005-10-16 Bristol-Myers Squibb Pharma Company Compuestos farmaceuticos para la formacion de imagenes de trastornos angiogenicos.
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
AU1908000A (en) 1998-11-06 2000-05-29 Basf Aktiengesellschaft Inhibition of the formation of vascular hyperpermeability
US6312665B1 (en) 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
WO2000055198A1 (en) * 1999-03-12 2000-09-21 Human Genome Sciences, Inc. 50 human secreted proteins
AU3249300A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. 47 human secreted proteins
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US6294525B1 (en) 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
GB9928950D0 (en) 1999-12-07 2000-02-02 Metris Therapeutics Limited Binding protein
EP1248642A4 (en) 2000-01-18 2005-05-18 Ludwig Inst Cancer Res PEPTIDOMIMETIC INHIBITOR OF VEGF AND VEGF-C AND -D
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
CA2399022A1 (en) 2000-02-04 2001-08-09 Supratek Pharma Inc. Ligand for vascular endothelial growth factor receptor
AU3988401A (en) 2000-02-25 2001-09-03 Ludwig Inst Cancer Res Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins
CA2401665A1 (en) 2000-03-02 2001-09-07 Ludwig Institute For Cancer Research Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor d
US20020102260A1 (en) 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
US6769080B2 (en) * 2000-03-09 2004-07-27 Texas Instruments Incorporated Scan circuit low power adapter with counter
US20010031485A1 (en) 2000-03-22 2001-10-18 Sibtech, Inc. Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments
EP1265635A1 (en) 2000-03-22 2002-12-18 Glaxo Group Limited Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
JP2003528632A (ja) 2000-03-31 2003-09-30 インスティティ・パスツール 血管内皮成長因子（ｖｅｇｆ）−媒介性脈管形成を阻害するペプチド、該ペプチドをエンコードするポリヌクレオチド及びその使用方法
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001259195A1 (en) 2000-04-28 2001-11-12 Glaxo Group Limited Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses
JP2004501091A (ja) 2000-05-03 2004-01-15 ルードヴィッヒ　インスティテュート　フォー　キャンサー　リサーチ 血管内皮成長因子レセプタ−３のみを活性化する方法とその利用法
KR100457350B1 (ko) 2000-06-01 2004-11-16 이경림 ＩｇＥ-의존적 히스타민 방출인자(ＨＲＦ)의 수용체,ＨＲＦ 결합 펩타이드 및 그들을 코딩하는 핵산, 및그들의 용도
EP1166799A1 (en) 2000-06-28 2002-01-02 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II)
EP1166798A1 (en) 2000-06-23 2002-01-02 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/ Tie receptor function and their use
MXPA02011897A (es) 2000-06-23 2003-04-22 Schering Ag Combinaciones y composiciones que interfieren con vegf/receptor de vegf y la funcion de angiopoyetina/tie y su uso (ii).
US7175844B2 (en) 2000-07-18 2007-02-13 Joslin Diabetes Center, Inc. Methods of modulating fibrosis
US20020091082A1 (en) 2000-09-13 2002-07-11 Aiello Lloyd P. Methods of modulating symptoms of hypertension
FR2814744B1 (fr) 2000-10-04 2002-11-29 Commissariat Energie Atomique Cyclopeptides, leur procede de preparation et leur utilisation comme inhibiteur ou activateur de l'angiogenese
US20030082103A1 (en) 2000-10-11 2003-05-01 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
WO2002083849A2 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
JP2005518185A (ja) * 2001-06-04 2005-06-23 キュラジェン コーポレイション 新規タンパク質およびそれをコード化する核酸
WO2003000844A2 (en) * 2001-06-22 2003-01-03 Incyte Genomics, Inc. Protein modification and maintenance molecules
AU2002362461A1 (en) 2001-10-01 2003-04-14 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
US6766860B2 (en) * 2002-02-22 2004-07-27 Globalsantafe Corporation Multi-activity offshore drilling facility having a support for tubular string
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
JP2005524710A (ja) 2002-05-06 2005-08-18 ジェネンテック・インコーポレーテッド 骨欠陥の治療へのｖｅｇｆの用途
PT2949658T (pt) * 2003-03-03 2018-10-18 Bracco Suisse Sa Péptidos que ligam especificamente o recetor de hgf (cmet) e utilizações dos mesmos
ES2428964T3 (es) * 2005-12-09 2013-11-12 Bracco Suisse Sa Conjugados de vectores específicos de una diana-fosfolípidos
ES2398618T3 (es) * 2008-02-25 2013-03-20 Nestec S.A. Selección de fármacos para terapia del cáncer de mama utilizando matrices de anticuerpos
US9801473B2 (en) 2012-09-13 2017-10-31 Kids Ii, Inc. Play yard with removable liner
EP3020171B1 (en) 2013-07-12 2017-12-20 Telefonaktiebolaget LM Ericsson (publ) Method for enabling control of data packet flows belonging to different access technologies

Also Published As

Publication number Publication date
US20050214859A1 (en) 2005-09-29
ES2396368T3 (es) 2013-02-21
AU2010235865B2 (en) 2012-11-15
EP1603935A2 (en) 2005-12-14
PL1944312T3 (pl) 2012-12-31
EP2949658B1 (en) 2018-08-08
AU2010235865A1 (en) 2010-11-11
CA2517939A1 (en) 2004-09-16
JP2014159434A (ja) 2014-09-04
US8044175B2 (en) 2011-10-25
EP2284180A3 (en) 2011-10-05
EP2949658A3 (en) 2016-01-13
EP1944312A1 (en) 2008-07-16
JP6216280B2 (ja) 2017-10-18
US20110311446A1 (en) 2011-12-22
US9845340B2 (en) 2017-12-19
US20100260672A1 (en) 2010-10-14
EP1944312B1 (en) 2012-06-27
CY1120683T1 (el) 2019-12-11
EP2284180B1 (en) 2015-09-09
EP2949658A2 (en) 2015-12-02
AU2004217894B2 (en) 2010-07-15
JP5466350B2 (ja) 2014-04-09
CA2517939C (en) 2015-11-24
WO2004078778A2 (en) 2004-09-16
HUE039154T2 (hu) 2018-12-28
SI2949658T1 (sl) 2018-10-30
JP2011037872A (ja) 2011-02-24
JP2017019787A (ja) 2017-01-26
EP1603935A4 (en) 2007-03-21
DK2284180T3 (en) 2015-12-21
ES2557286T3 (es) 2016-01-25
ES2692166T3 (es) 2018-11-30
DK2949658T3 (en) 2018-10-01
US20150218218A1 (en) 2015-08-06
EP2284180A2 (en) 2011-02-16
WO2004078778A3 (en) 2004-11-18
JP2007524598A (ja) 2007-08-30
US20120039802A1 (en) 2012-02-16
AU2004217894A1 (en) 2004-09-16
US20100261875A1 (en) 2010-10-14
PL2949658T3 (pl) 2018-11-30
JP5876644B2 (ja) 2016-03-02
JP6374913B2 (ja) 2018-08-15
US9000124B2 (en) 2015-04-07

Similar Documents

Publication Publication Date Title
SI2949658T1 (sl) Peptidi, ki specifično vežejo HGF receptor (cMet) in njihove uporabe
IL183353A0 (en) Polypeptides that bind br3 and uses thereof
EP1722808A4 (en) EGF RECEPTOR EPITOD PEPTIDES AND THEIR USES
EP1636334A4 (en) RECOMBINANT ANTI-CD30 ANTIBODIES AND USES THEREOF
HK1091116A1 (en) Recombinant il-9 antibodies and uses thereof
IL200404A0 (en) 191P4D12(b) PROTEINS, POLYNUCLEOTIDES ENCODING THE SAME; ANTIBODIES BINDING THERETO AND USES THEREOF
EP1499352A4 (en) ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES
EP1746902A4 (en) MULTILEKTIN AFFINICHROMATOGRAPHY AND USE THEREOF
HK1089110A1 (en) Recombinant lubricin molecules and uses thereof
EP1835027A4 (en) NEW ANTIGEN PEPTIDE AGAINST CANCER AND APPLICATIONS
EP1829969A4 (en) NOVEL POLYPEPTIDE AND USE THEREOF
AU2003288809A8 (en) Peptides that bind of the vegfr-2
EP1614695A4 (en) POLYPEPTIDE
GB0309064D0 (en) Modified peptides and their uses
AU2003285892A8 (en) Bace binding peptides and uses thereof
HK1209050A1 (en) Survivin-derived peptides and use thereof
EP1699809A4 (en) PEPTIDE FROM AMNIOTIC LIQUID AND USES THEREOF
GB0401303D0 (en) Polypeptide and uses thereof
GB0323193D0 (en) Peptides and uses thereof
GB0312990D0 (en) Peptides and uses thereof
GB0425731D0 (en) Isolated peptides and uses thereof
GB0321401D0 (en) Antibodies,polypeptides and uses thereof
GB0422110D0 (en) Recombinant proteins
IL149179A0 (en) FcyRII-BINDING PEPTIDES AND USES THEREOF
GB0306261D0 (en) Polypeptide